609 Restoring Immune Responsiveness in Periphery and Tumor with Mrna-4359, an Mrna-Based Therapy Encoding PD-L1 and IDO1 Peptides, Plus Pembrolizumab in Checkpoint Inhibitor Resistant/refractory Melanoma